The expression of LILRA2 gene is lower in liver cancer patients, suggesting that the low expression of this gene in such patients may be a pivotal factor contributing to their insensitivity to chemotherapy drugs and poor response to targeted therapy. This evidence concerns the gene LILRA2 and liver cancer.